Extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted
US patent granted extending bexmarilimab protection to 2040 for Clever-1 positive cancers.
- Original patent expiry 2037
- New patent expiry February 2040
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Press Release | August 08, 2025 at 10:30:00 EEST |
Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted
Faron has been granted a patent for treatment of Clever-1 positive cancers with bexmarilimab and related structures in the USA.
This extends key patent rights around bexmarilimab from an initial 2037 to 2040 in the USA.
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 12,371,486 for treatment of Clever-1 positive cancers with bexmarilimab and related structures that would bind to Clever-1 molecule for the wanted re-programming effect.
The patent is granted based on divisional application from the original “composition of matter” patent covering the structure of bexmarilimab. The original application included the composition matter claims as well as the treatment method. The new granted patent covers treating cancers that have Clever-1 positive cells in the tumour microenvironment with such structures. As previously announced a patent covering the composition of matter of bexmarilimab was already granted four years ago with patent life up to 2037 without extensions. Based on the long application process of the division application, the term of the newly granted patent has been adjusted beyond the standard twenty years lasting until February 2040.
“This significantly extends our key patent life on the use of bexmarilimab for the treatment of relevant cancers, that have Clever-1 positive tumour associated macrophages or blasts cells, such as in AML & MDS.”, says Faron’s CEO Juho Jalkanen. ”The patent family around targeting Clever-1 in cancer is strong and we believe bexmarilimab will enjoy a long patent life once marketed, given how far it is in clinical development already”, continues Dr. Jalkanen.
About bexmarilimab
About Faron Pharmaceuticals Ltd.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.